• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Oasmia Pharmaceutical

edit

Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on in-house research within nanotechnology and company patents.

Milestones

edit

• 
  Oasmia Pharmaceutical added Weine Nejdemo as CFO.
  Posted 10/31/10 at 8:12pm
• 
  Oasmia Pharmaceutical added Julian Aleksov as CEO.
  Posted 10/31/10 at 8:12pm
• 
  Went public with stock symbol NASDAQ:OMX.
  Posted 10/31/10 at 8:15pm
• 
  Oasmia Pharmaceutical received $10.2M (kr75M) in Venture Round funding. (7/22/10)
  Posted 10/31/10 at 8:12pm via oasmia.com

Videos

Screenshots

edit

Stock Price

Sources

1. Oasmia enters into SEK 75 million SEDA-agreement (oasmia.com) [edit]